.svg)
.svg){kind=small}
Only 29 drug developers boasted a blockbuster drug product in 2023. That tally includes Adcetris from SeaGen, which was acquired by Pfizer during the year.
Seven drug developers wielded at least 10 blockbusters during the period. This group had an average market valuation of $228 billion, with GlaxoSmithKline ($87.8 billion) being the smallest and AbbVie ($319 billion) being the largest pure-play drug developer. The latter excludes Johnson & Johnson ($392 billion), which has a large medical devices segment.
.svg){kind=icon}
-cropped.svg)
.svg){kind=small}